Back to Search Start Over

Recombinant alpha-2B interferon treatment for childhood T--lymphoblastic disease in relapse. A Pediatric Oncology Group Phase II study.

Recombinant alpha-2B interferon treatment for childhood T--lymphoblastic disease in relapse. A Pediatric Oncology Group Phase II study.

Authors :
Lauer SJ
Ochs J
Pollock BH
Buchanan GR
Source :
Cancer [Cancer] 1994 Jul 01; Vol. 74 (1), pp. 197-202.
Publication Year :
1994

Abstract

Background: Children with chemotherapy refractory T-cell lymphoblastic leukemia/lymphoma were given alpha-interferon (alpha-IFN) to evaluate the efficacy and toxicity of this biologic response modifier.<br />Methods: Twenty children with T-cell acute lymphoblastic leukemia (T-cell ALL) in marrow relapse and one patient with mediastinal recurrence of T-cell non-Hodgkin's lymphoma (T-cell NHL) were enrolled. All patients had failed at least two previous multiagent drug trials. Recombinant alpha-IFN was given at 30 million U/M2/dose intravenously or subcutaneously for 10 doses over 14 days, followed by 3 doses per week until disease progression occurred.<br />Results: One child had a complete response (< 5% blasts) and three patients a partial response (5-25% blasts) in their bone marrow. All patients eventually showed signs of progressive disease. Significant toxicities included cardiac hypofunction in two patients and profound lethargy in two patients.<br />Conclusions: alpha-IFN is tolerated in children with T-cell ALL and T-cell NHL and has activity against chemotherapy resistant disease.

Details

Language :
English
ISSN :
0008-543X
Volume :
74
Issue :
1
Database :
MEDLINE
Journal :
Cancer
Publication Type :
Academic Journal
Accession number :
8004576
Full Text :
https://doi.org/10.1002/1097-0142(19940701)74:1<197::aid-cncr2820740131>3.0.co;2-9